藥明康德(02359.HK):擬以競價交易方式回購公司A股
格隆匯2月2日丨藥明康德(02359.HK)發佈公吿,公司擬通過上交所以競價交易方式回購公司A股。回購方案已於2024年2月1日舉行的第三屆董事會第七次會議上獲審議及批准。
回購的A股將全部用於註銷並減少註冊資本。按照股份回購的資金總額人民幣10億元,以股份回購價格上限人民幣100.90元╱股(含)計算,預計將予回購的A股數量約為991.08萬股A股,約佔本公司於本公吿日期已發行股本總額的0.34%。股份回購的價格上限不超過人民幣100.90元╱股(含),即不超過董事會審議及批准回購方案的決議案前30個交易日公司A股交易均價的150%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.